Value through Innovation01 September 2014

Boehringer Ingelheim Press Releases

See the latest Boehringer Ingelheim news releases. To quickly find all news releases on a specific topic, please use the fulltext search.

Press Release Archive

back 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16
01.09.2014

Extensive experience in clinical practice and expanding research programme support use of Pradaxa® for clot prevention

- For Non-US/Non-UK/Non-Canadian Media
01.09.2014

Boehringer Ingelheim Animal Health sees freshly mixed swine vaccines as its way forward

01.09.2014

Boehringer Ingelheim to present comprehensive data supporting broad respiratory portfolio in COPD, asthma and IPF at ERS 2014

- For media outside UK, US and Canada
25.08.2014

New Pradaxa® data to be presented at the ESC Congress 2014

- For Non-US/Non-UK/Non-Canadian Media
22.08.2014

Boehringer Ingelheim Animal Health celebrates 20 years of PRRS control and innovation

19.08.2014

First patients enrolled in study to evaluate dabigatran etexilate after PCI with stenting

- For Non-US/Non-UK/Non-Canadian Media
11.08.2014

First half year 2014: Boehringer Ingelheim meets challenges

04.08.2014

Boehringer Ingelheim receives two FDA approvals

- For Non-US/Non-UK media only
23.07.2014

Pradaxa® (dabigatran etexilate) Video Statement

- For media outside UK, U.S. and Canada
23.07.2014

Efficacy and Safety Profile of Pradaxa® (dabigatran etexilate) Repeatedly Confirmed

- For media outside UK, U.S. and Canada
22.07.2014

Boehringer Ingelheim Establishes a Research Alliance with the University of Toronto, the Toronto-based University Health Network and the Mount Sinai Hospital to investigate new therapeutic concepts in the field of ubiquitin signalling biology

16.07.2014

Boehringer Ingelheim’s investigational therapy nintedanib* receives the first FDA breakthrough therapy designation in IPF

- For non-US media only
08.07.2014

Boehringer Ingelheim’s volasertib showed in a Phase II study an improvement in overall survival in older AML patients

- For media outside of the US/UK only
07.07.2014

Judit Makara wins Boehringer Ingelheim’s FENS Award 2014 for Exceptional Research in Neuroscience

- For Non-US, Non-UK Media Only
30.06.2014

U.S. FDA grants Breakthrough Therapy Designation to Pradaxa® (dabigatran etexilate) specific investigational antidote

- For media outside of the U.S., the UK & Canada only
27.06.2014

CHMP Recommends Lilly and Boehringer Ingelheim’s New Insulin Glargine Product for Approval in the European Union

- For Non-U.S. and Non-U.K. Media
20.06.2014

Boehringer Ingelheim Statement on Hepatitis C drug development

- For media outside of the US, the UK only
20.06.2014

New Pradaxa® clinical study to explore practical management of patients with atrial fibrillation undergoing ablation

- For media outside of the U.S., the UK & Canada only
back 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16